Author of

• 12648

  +

  P3.11 - Poster Session 3 - NSCLC Novel Therapies (ID 211)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12695

    +

    P3.11-047 - Factors associated with brain metastasis in metastatic non-small cell lung cancer (ID 3133)

    09:30 - 09:30  |  Author(s): E. Browning
    • Abstract

    Background
    The brain is a common site of metastatic spread in non-small cell lung cancer that is often associated with morbidity and poorer survival. Previously, we have published that ALK, EGFR, or KRAS status alone was not associated with the presence of brain metastases at diagnosis. Additional methods are needed to predict which patients are at risk for presenting with brain metastasis at diagnosis. The purpose of our study was to develop a more detailed predictive model to identify patients at high risk of brain metastasis at diagnosis.

    Methods
    Patients with metastatic non-small cell lung cancer in whom molecular analysis was conducted in the Colorado Molecular Correlates Laboratory were identified. Data were collected through retrospective review of charts of 120 patients. Characteristics at the time of diagnosis were collected, including stage, tumor size, histology, age, ethnicity, molecular markers including the presence of EGFR, ALK, KRAS, or p53 mutation, and sites of metastatic disease, including brain, bone, liver, and adrenal metastasis. A logistic regression model was tested using backward elimination, with presence of brain metastasis at diagnosis as the outcome of interest.

    Results
    No statistically significant association was seen between the presence of brain metastasis and any of the above covariates. We examined the relationship between brain metastasis and KRAS mutation, even though this variable was not selected in the model selection procedure. The odds ratio for brain metastasis with KRAS mutation was 0.3714, indicating that patients with KRAS mutation have 63% lower odds of brain metastasis at diagnosis than patients without a KRAS mutation (95% exact confidence interval: 0.0825, 1.3321, p= 0.1184).

    Conclusion
    No significant association was observed between the presence of brain metastasis and various clinical presenting characteristics in patients with metastatic non-small cell lung cancer, including stage, tumor size, histology, age, ethnicity, molecular markers including the presence of EGFR, ALK, KRAS, or p53 mutation, and sites of metastatic disease, including brain, bone, liver, and adrenal metastasis.